Open-Label Extension Study of Trofinetide for Rett Syndrome
Terminated · Phase 3 · NCT04776746
Conditions: Rett Syndrome
At a glance
- Research payments reported, 2025
- $286,888
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 77
About the trial
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Tested
- trofinetide (drug)
- Dates
- Started 2020-11-08; completion 2023-06-30
- Results posted
- Yes
To investigate the safety and tolerability of continued long-term treatment with oral trofinetide in girls and women with Rett syndrome
From ClinicalTrials.gov, last updated 2024-09-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Acadia Pharmaceuticals Inc reported $286,888 in research payments for this study in 2025 (10 payments).
Products named: Acp-101
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Hussein D. Abdul-latif, M.D. Pediatric Endocrinology · Birmingham, AL
- Arthur A. Beisang, MD Pediatrics · Saint Paul, MN
- Robin C. Ryther, MD Neurology · Saint Louis, MO
- Steven A. Skinner, MD Medical Genetics · Greenwood, SC
- Italo Biaggioni, MD Clinical Pharmacology · Nashville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Washington University $113,120
- Vanderbilt University Medical Center, TN $112,850
- Greenwood Genetic Center Inc $30,610
- University of Alabama Hospital, AL $16,558
- Gillette Childrens Specialty Hospital, MN $13,750
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.